ClinicalTrials.gg
RecruitingNCT06002633PACSUpdated Apr 15, 2026

Approach-Avoidance and Alcohol Challenge Study in PTSD

An interventional study of Alcohol and Placebo in Post-Traumatic Stress Disorder and Alcohol Drinking, sponsored by University of Texas at Austin. Recruiting at 1 site in United States. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by University of Texas at Austin · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Stress Disorders, Post-Traumatic by University of Texas at Austin — 6 open to participants now, 6 under way, none of them phase 3. Stress Disorders, Post-Traumatic · University of Texas at Austin.

Planned enrollment
2nd of 20
200 · median 65
Started
2023
the only one that year
No phase
15 of 20
6 open now
Registered
16th of 20
by date

Among the 20 studies in Stress Disorders, Post-Traumatic by University of Texas at Austin, this one is the 2nd largest by planned enrollment, is the only one that started in 2023, is one of 15 with no phase, and was the 16th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

6 of the 20 studies in Stress Disorders, Post-Traumatic by University of Texas at Austin are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 21 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Stress Disorders, Post-Traumatic by University of Texas at Austin, or all of them as a file.
02

Study summary

Individuals with posttraumatic stress disorder (PTSD) have greater prevalence of alcohol use disorders (AUDs), with this comorbidity associated with worse illness outcomes, yet there remains limited mechanistic understanding of how PTSD confers risk for AUD. Understanding risk factors that associate with and predict the development of AUDs in PTSD could inform interventions and prevention efforts to reduce the rate of this comorbidity and improve outcomes of both disorders. Identifying predictors of risk requires longitudinal studies in PTSD aimed at capturing the mechanisms leading to the emergence of AUDs. There is growing evidence PTSD is related to biased decision-making during approach-avoidance conflict. Alcohol is also suggested to alter approach-avoidance decision-making. AUDs and acute alcohol intoxication is associated with a bias to seek out reward despite the possibility of threat (e.g., contributing to relapse following alcohol cue exposure and risky behavior during intoxication respectively). Alcohol-induced changes in approach-avoidance decision-making have not been investigated in the context of PTSD, but emerging data support the investigators' hypothesis that an interaction between alcohol and approach-avoidance conflict in PTSD may occur and contribute to risk for alcohol misuse and development of alcohol problems. No current data, cross-sectional or longitudinal, have tested the role of alcohol-induced changes in approach-avoidance conflict as a mechanism of risk for AUD among individuals with PTSD. To address this gap, the investigators propose to leverage the group's expertise in placebo-controlled alcohol administration procedures, longitudinal modeling, functional neuroimaging, and computational neuroscience approaches to investigate the effects of acute alcohol on approach-avoidance decision-making and mediating changes in multivariate neurocircuitry patterns in limbic, striatal, and salience networks.

Read the detailed description

The proposed study will test the conceptual model positing that acute alcohol alters the relative bias in computational mechanisms for threat vs reward, thereby decreasing avoidance to threat and increasing approach to reward in adults with PTSD, and through this mechanism increases risk for heavier alcohol use over time. Research aims are to identify alcohol-induced changes in approach-avoidance decision-making and mediating neural networks that predict alcohol use and symptoms of AUDs over a one-year follow-up period in adults with PTSD, compared to adults with interpersonal violence exposure but no PTSD and healthy comparison adults. Essential to successfully improving clinical prognosis in PTSD are research results that enable better prediction, diagnosis, and treatment based on the individual. There is a paucity of human clinical research investigating interactions between acute alcohol exposure and PTSD that may drive risk for development of AUDs following trauma. Data could identify brain and behavioral mechanisms explaining how alcohol alters an important domain of PTSD contributing to risk for alcohol misuse and development of alcohol problems. Results could pave way for development of novel behavioral and pharmacological methods to treat PTSD and decrease risk for developing comorbid AUDs.

03

Conditions studied

  • Post-Traumatic Stress Disorder
  • Alcohol Drinking
04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  1. Inclusion criteria for all participants:

    • between 21 and 60 years of age
    • having consumed at least 4 (men) or 3 (women) drinks on at least two occasions over the last year
  2. Inclusion criteria for PTSD participants:

    - Meeting diagnostic criteria for PTSD, confirmed by structured interview

  3. For all subjects exclusion criteria include:

    • history of significant medical illness, particularly if possible changes in cerebral tissue
    • neurologic abnormality including significant head trauma (loss of consciousness of ≥5-min)
    • full Scale IQ \<85
    • to MRI scanning
    • positive pregnancy test
    • severe alcohol use disorder
    • current severe cannabis use disorder
    • any current substance use disorder (other than alcohol, cannabis, or nicotine)
    • scores > 15 on the alcohol Use Disorders Identification Test (AUDIT; part of phone screen)
    • ever being in an abstinence-oriented treatment program for alcohol use
    • reporting wanting to quit drinking but not being able to
    • any medical, religious, or other reasons for not drinking alcohol
    • history of heart attack, heart trouble, high blood pressure, diabetes, or liver disease
    • an adverse reaction to alcoholic beverages
    • reporting never consuming 4 (men) or 3 (women) or more drinks on at least two occasions over the last year
    • unwillingness to have a friend or family member drive them home after the alcohol administration sessions
  4. Additional exclusion criteria for participants in PTSD and IPV-exposed but no PTSD groups:

    • not taking medications for >4 weeks (i.e. participants must be stable on meds)
    • acute suicidality with intent
  5. Additional exclusion criteria for participants in IPV-exposure but no PTSD group:

    - history of PTSD

  6. Additional exclusion criteria for healthy comparison subjects also include:

    • any prior psychiatric hospitalizations
    • lifetime history of a neurodevelopmental disorder, affective disorder, psychotic disorder, suicide attempt, or eating disorder
    • greater than 1 month of lifetime psychotropic medication
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Alcohol

    Participants will drink beverages containing alcohol.

    Other: Alcohol

  • Placebo comparator
    Placebo

    Participants will drink beverages containing a very low dose of alcohol (placebo condition).

    Other: Placebo

Interventions

  • OtherAlcohol

    Participants will consume beverages containing alcohol.

  • OtherPlacebo

    Participants will consume beverages containing a very low dose of alcohol (placebo condition).

06

What researchers measure

Primary outcomes

  1. ratio of approach to avoidance choices

    the number of trials on which individuals chose to avoid vs approach will be quantified during the task and compared between placebo and alcohol conditions

    Time frame: 1 week

  2. changes in dorsal anterior cingulate cortex activation

    the degree of activation on high conflict trials (relative to low conflict trials) on the task in the dorsal anterior cingulate will be quantified and compared between the placebo and alcohol conditions

    Time frame: 1 week

  3. Relations between ratio of approach to avoidance choices with alcohol use over a one-year follow-up

    The relationship between the number of trials on which individuals chose to avoid vs approach during the alcohol session with alcohol use over a one-year follow up will be modeled. Number of drinks consumed per day over the course of the follow-up year will be used to calculate Area Under the Curve (AUC), with AUC as the dependent variable.

    Time frame: 1 year

  4. Relations between changes in dorsal anterior cingulate cortex activation with alcohol use over a one-year follow-up

    The relationship between the degree of activation on high conflict trials (relative to low conflict trials) on the task in the dorsal anterior cingulate during the alcohol session with alcohol use over a one-year follow up will be modeled. Number of drinks consumed per day over the course of the follow-up year will be used to calculate Area Under the Curve (AUC), with AUC as the dependent variable.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — After study completion and publication of finding, functional neuroimaging data and behavior data collected following alcohol and placebo conditions will be shared.

Supporting information: Statistical analysis plan

Time frame: We will complete all our analyses and publish results and methodologies in scientific journals before the data are available to the research community. Data will be made available following 6 months after publication.

Access criteria: We will be collecting identifying information. Even though the final dataset will be stripped of identifiers prior to release for sharing, we believe that there remains the possibility of deductive disclosure of subjects with unusual characteristics. Thus, we will make the data and associated documentation available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for May 2028, 55 months after the start.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 55 months is above that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2023
First posted
Aug 21, 2023
StartActual
Oct 23, 2023
Primary completionEst.
May 31, 2028
CompletionEst.
May 31, 2028
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06002633
Responsible party
Elizabeth Thomas Cox Lippard (Associate Professor, University of Texas at Austin) — Principal investigator
First posted
Aug 21, 2023
Start date
Oct 23, 2023
Primary completion
May 31, 2028 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Apr 15, 2026

Study contacts

Research Coordinator
Contact
behavioral.neuroimaging@austin.utexas.edu
5124955198
Elizabeth Lippard, PhD
principal investigator · University of Texas at Austin
Josh Cisler, PhD
principal investigator · University of Texas at Austin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion